Advertisement
Screener

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Depreciation

2.8 / 5 stars · 68/120 Roast Me

ADAPTIVE BIOTECHNOLOGIES CORPORATION Depreciation

ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Depreciation of $6.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:Depreciation · last filed 2026-08-04

  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for the quarter ending 2026-06-30 was $3.27M, a 19.78% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for the quarter ending 2026-03-31 was $3.42M, a 20.73% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for the quarter ending 2025-12-31 was $3.77M, a 6.32% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for the quarter ending 2025-09-30 was $3.98M, a 4.47% decline year-over-year.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for fiscal 2025 was $16.13M, a 8.08% decline from fiscal 2024.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for fiscal 2024 was $17.55M, a 14.51% decline from fiscal 2023.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for fiscal 2023 was $20.53M, a 6.82% increase from fiscal 2022.
  • ADAPTIVE BIOTECHNOLOGIES CORPORATION depreciation for fiscal 2022 was $19.22M, a 56.85% increase from fiscal 2021.
Period endDepreciation 3 monthDepreciation 6 monthDepreciation 9 monthDepreciation 12 month
2026-06-30$3.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$6.69M
10-Q · filed 2026-08-04
$10.46M
derived: sum of 3 quarters · filed 2026-08-04
$14.43M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$3.42M
10-Q · filed 2026-05-05
$7.18M
derived: sum of 2 quarters · filed 2026-05-05
$11.16M
derived: sum of 3 quarters · filed 2026-05-05
$15.24M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$3.77M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$7.74M
derived: sum of 2 quarters · filed 2026-02-26
$11.82M
derived: sum of 3 quarters · filed 2026-08-04
$16.13M
10-K · filed 2026-02-26
2025-09-30$3.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$8.06M
derived: sum of 2 quarters · filed 2026-08-04
$12.37M
10-Q · filed 2025-11-05
$16.39M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$4.08M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$8.39M
10-Q · filed 2026-08-04
$12.41M
derived: sum of 3 quarters · filed 2026-08-04
$16.57M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$4.31M
10-Q · filed 2026-05-05
$8.33M
derived: sum of 2 quarters · filed 2026-05-05
$12.49M
derived: sum of 3 quarters · filed 2026-05-05
$17.07M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$4.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$8.18M
derived: sum of 2 quarters · filed 2026-02-26
$12.76M
derived: sum of 3 quarters · filed 2026-02-26
$17.55M
10-K · filed 2026-02-26
2024-09-30$4.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$8.74M
derived: sum of 2 quarters · filed 2025-11-05
$13.53M
10-Q · filed 2025-11-05
$18.50M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$4.58M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$9.37M
10-Q · filed 2025-08-05
$14.33M
derived: sum of 3 quarters · filed 2026-02-26
$19.67M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$4.79M
10-Q · filed 2025-05-01
$9.75M
derived: sum of 2 quarters · filed 2026-02-26
$15.09M
derived: sum of 3 quarters · filed 2026-02-26
$20.32M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$4.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$10.30M
derived: sum of 2 quarters · filed 2026-02-26
$15.53M
derived: sum of 3 quarters · filed 2026-02-26
$20.53M
10-K · filed 2026-02-26
2023-09-30$5.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$10.56M
derived: sum of 2 quarters · filed 2024-11-07
$15.57M
10-Q · filed 2024-11-07
$20.43M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$5.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$10.23M
10-Q · filed 2024-08-01
$15.09M
derived: sum of 3 quarters · filed 2025-03-03
$20.05M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$5.00M
10-Q · filed 2024-05-07
$9.86M
derived: sum of 2 quarters · filed 2025-03-03
$14.82M
derived: sum of 3 quarters · filed 2025-03-03
$19.59M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31$4.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$9.81M
derived: sum of 2 quarters · filed 2025-03-03
$14.58M
derived: sum of 3 quarters · filed 2025-03-03
$19.22M
10-K · filed 2025-03-03
2022-09-30$4.96M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
$9.73M
derived: sum of 2 quarters · filed 2023-11-09
$14.36M
10-Q · filed 2023-11-09
$18.78M
derived: sum of 4 quarters · filed 2024-02-29
2022-06-30$4.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02
$9.41M
10-Q · filed 2023-08-02
$13.83M
derived: sum of 3 quarters · filed 2024-02-29
$16.93M
derived: sum of 4 quarters · filed 2024-02-29
2022-03-31$4.64M
10-Q · filed 2023-05-03
$9.06M
derived: sum of 2 quarters · filed 2024-02-29
$12.16M
derived: sum of 3 quarters · filed 2024-02-29
$14.64M
derived: sum of 4 quarters · filed 2024-02-29
2021-12-31$4.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29
$7.52M
derived: sum of 2 quarters · filed 2024-02-29
$10.00M
derived: sum of 3 quarters · filed 2024-02-29
$12.25M
10-K · filed 2024-02-29
2021-09-30$3.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$5.58M
derived: sum of 2 quarters · filed 2022-11-03
$7.83M
10-Q · filed 2022-11-03
$9.76M
derived: sum of 4 quarters · filed 2023-02-14
2021-06-30$2.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$4.73M
10-Q · filed 2022-08-03
$6.66M
derived: sum of 3 quarters · filed 2023-02-14
$8.37M
derived: sum of 4 quarters · filed 2023-02-14
2021-03-31$2.25M
10-Q · filed 2022-05-04
$4.18M
derived: sum of 2 quarters · filed 2023-02-14
$5.89M
derived: sum of 3 quarters · filed 2023-02-14
$7.47M
derived: sum of 4 quarters · filed 2023-02-14
2020-12-31$1.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14
$3.64M
derived: sum of 2 quarters · filed 2023-02-14
$5.21M
derived: sum of 3 quarters · filed 2023-02-14
$6.77M
10-K · filed 2023-02-14
2020-09-30$1.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$3.29M
derived: sum of 2 quarters · filed 2021-11-03
$4.84M
10-Q · filed 2021-11-03
$6.49M
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$1.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$3.13M
10-Q · filed 2021-08-04
$4.78M
derived: sum of 3 quarters · filed 2022-02-15
$6.41M
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$1.55M
10-Q · filed 2021-05-05
$3.20M
derived: sum of 2 quarters · filed 2022-02-15
$4.84M
derived: sum of 3 quarters · filed 2022-02-15
$6.28M
derived: sum of 4 quarters · filed 2022-02-15
2019-12-31$1.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$3.28M
derived: sum of 2 quarters · filed 2022-02-15
$4.73M
derived: sum of 3 quarters · filed 2022-02-15
$6.09M
10-K · filed 2022-02-15
2019-09-30$1.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
$3.08M
derived: sum of 2 quarters · filed 2020-11-10
$4.45M
10-Q · filed 2020-11-10
$5.61M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30$1.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$2.81M
10-Q · filed 2020-08-10
$3.98M
derived: sum of 3 quarters · filed 2021-02-24
$5.01M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31$1.36M
10-Q · filed 2020-05-12
$2.53M
derived: sum of 2 quarters · filed 2021-02-24
$3.57M
derived: sum of 3 quarters · filed 2021-02-24
2018-12-31$1.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$2.20M
derived: sum of 2 quarters · filed 2021-02-24
$4.30M
10-K · filed 2021-02-24
2018-09-30$1.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$3.14M
10-Q · filed 2019-11-12
2018-06-30$2.10M
10-Q · filed 2019-08-13
2017-12-31$4.10M
10-K · filed 2020-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Greenland Mines Ltd (GRML)United States$2.362B